Stryker completes acquisition of MOLLI Surgical

Rhea-AI Summary

Stryker (NYSE:SYK) has completed the acquisition of MOLLI Surgical Inc., a private company specializing in wire-free soft tissue localization technology for breast conserving surgery. This acquisition strengthens Stryker's commitment to advancing surgical solutions in breast cancer care. The MOLLI 2 localization system offers ease of use and reliability for efficient surgical workflows. Key features include:

- MOLLI Marker: Smallest on the market at 3.2 mm, detectable in dense breasts and through hematoma
- MOLLI 2 tablet: Provides surgeons with real-time feedback including distance, visual, auditory, and 3D directional guidance

This acquisition complements Stryker's existing breast cancer portfolio, which includes SPY fluorescence imaging technology for lymphatic mapping and lighted retractors.

Positive

• Acquisition strengthens Stryker's position in breast cancer surgical solutions
• MOLLI 2 system offers advanced features for improved surgical efficiency
• Complements existing Stryker portfolio in breast cancer space

Negative

• None.

SAN JOSE, California, USA, July 31, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's commitment to advancing surgical solutions in breast cancer care.

The MOLLI 2 localization system is designed for ease of use and reliability to support a more efficient surgical workflow. The MOLLI Marker is the smallest on the market at 3.2 mm and is detectable in dense breasts and through hematoma. The MOLLI 2 tablet provides surgeons with four real-time types of feedback: distance, visual, auditory and 3D directional guidance.

"Stryker is dedicated to helping oncology surgeons advance surgical treatment through continual innovation and strategic partnerships," said Andrés Rosales, vice president and general manager of Stryker's Endoscopy business. "The acquisition of MOLLI Surgical represents a significant step forward in our goal to provide surgeons with the most advanced tools to improve patient care. MOLLI Surgical complements our existing portfolio in the breast cancer space, which includes our SPY fluorescence imaging technology for lymphatic mapping and lighted retractors."

About Stryker 
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

Media contact
Sherri Oakson
Stryker
Senior Director, Communications, MedSurg and Neurotechnology Group 
sherri.oakson@stryker.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-completes-acquisition-of-molli-surgical-302210345.html

SOURCE Stryker

FAQ

What company did Stryker (SYK) acquire on July 31, 2024?

Stryker (SYK) acquired MOLLI Surgical Inc., a privately held company specializing in wire-free soft tissue localization technology for breast conserving surgery.

What are the key features of MOLLI Surgical's technology acquired by Stryker (SYK)?

MOLLI Surgical's technology includes the MOLLI 2 localization system with the smallest marker on the market (3.2 mm) and a tablet providing real-time feedback including distance, visual, auditory, and 3D directional guidance for surgeons.

How does the MOLLI Surgical acquisition complement Stryker's (SYK) existing portfolio?

The acquisition complements Stryker's existing breast cancer portfolio, which includes SPY fluorescence imaging technology for lymphatic mapping and lighted retractors, further strengthening their position in breast cancer surgical solutions.

What is the significance of the MOLLI Surgical acquisition for Stryker (SYK) in the breast cancer care market?

The acquisition represents a significant step forward in Stryker's goal to provide surgeons with advanced tools to improve patient care in breast cancer treatment, strengthening their commitment to advancing surgical solutions in this field.